Leerink Partnrs Has Weak Outlook for DexCom FY2025 Earnings

DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for DexCom in a research report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of $2.06 for the year, down from their prior estimate of $2.07. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s Q4 2025 earnings at $0.66 EPS.

A number of other analysts also recently commented on the company. Leerink Partners decreased their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Stifel Nicolaus raised their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Finally, Sanford C. Bernstein lifted their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Performance

Shares of DXCM opened at $78.10 on Wednesday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $30.51 billion, a price-to-earnings ratio of 46.77, a PEG ratio of 2.38 and a beta of 1.17. The stock has a 50 day moving average of $71.24 and a 200 day moving average of $88.44. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00.

Institutional Investors Weigh In On DexCom

Several large investors have recently made changes to their positions in DXCM. Jennison Associates LLC increased its holdings in shares of DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Two Sigma Advisers LP grew its position in DexCom by 182.7% in the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after acquiring an additional 739,000 shares in the last quarter. Canada Pension Plan Investment Board grew its position in DexCom by 189.1% in the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after acquiring an additional 435,401 shares in the last quarter. Finally, Intech Investment Management LLC grew its position in DexCom by 2,083.0% in the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after acquiring an additional 369,587 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,431 shares of company stock valued at $399,319 over the last ninety days. 0.30% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.